BridgeBio Pharma’s NDA for Acoramidis Accepted by FDA
The U.S. FDA has accepted BridgeBio Pharma's New Drug Application for acoramidis, an investigational drug for Transthyretin Amyloid Cardiomyopathy....
transthyretin amyloid cardiomyopathy
BridgeBio Secures $1.25 Billion in New Financing for Acoramidis Launch
BridgeBio Pharma has secured $1.25 billion in new financing as it prepares to launch its acoramidis heart-disease drug candidate....
BridgeBio Files for FDA Approval of Acoramidis in Transthyretin Amyloid Cardiomyopathy
BridgeBio Pharma has submitted its acoramidis drug candidate for FDA approval to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a heart...